Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer
Julia Wulfkuhle(University of California, San Francisco), Emanual Petricoin(George Mason University), Angela DeMichele(University of Pennsylvania), Richard B. Schwab(Center for Personalized Cancer Treatment), Laura van ‘t Veer, Lamorna Brown Swigart(University of California, San Francisco), Nola Hylton(University of California, San Francisco), Douglas Yee(University of Minnesota Medical Center), John Park(California Baptist University), Laura Sit(Memorial Sloan Kettering Cancer Center), Hope Rugo(University of California, San Francisco), Rosa I. Gallagher(George Mason University), Kathy S. Albain(Loyola University Chicago), Christina Yau(Hospital Authority), Laura J. Esserman(University of California, San Francisco), Gillian L. Hirst(University of California, San Francisco), Don Berry(University of California, San Francisco), Jo Chien(University of California, San Francisco), Denise Wolf(Lawrence Berkeley National Laboratory), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Smita Asare(Quantum Leap Healthcare Collaborative), Rita Nanda(University of Chicago)
Cited by 0
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k